-
Innovation Ranking
Innovation Ranking – Intercept Pharmaceuticals Inc
Intercept Pharmaceuticals Inc (Intercept) is a biopharmaceutical company that researches, develops, and commercializes treatments for non-viral, progressive liver diseases. It develops products using proprietary bile acid chemistry. The company’s lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor. The company is advancing OCA for the treatment of various other liver diseases. The company harnesses its proprietary bile acid chemistry to develop innovative drugs. It is also advancing INT-787, an FXR...
-
Product Insights
NewCerus Corp Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Cerus Corp Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Cerus Corp (Cerus) is a biomedical products company that focuses on the field of blood transfusion safety. It develops and commercializes Intercept blood system, which reduces the risk of transfusion-transmitted infections by inactivating a wide range of pathogens including viruses, bacteria, and parasites present in donated blood. The Intercept blood system is for use with blood components including platelets, plasma,...
-
Sector Analysis
Oman Defense Market Size, Trends, Budget Allocation, Regulations, Acquisitions, Competitive Landscape and Forecast to 2029
Oman Defense Market Report Overview The Oman defense budget is $8 billion in 2024. The country’s defense budget will grow at a CAGR of more than 2% during 2025-2029. This can be attributed to the rising arms race in the region to intercept the growing turbulence in neighboring countries such as Syria and Yemen. In addition, the increase in oil prices will facilitate increases in Oman's defense budget. Oman Defense Market Outlook, 2024-2029 ($ Billion) Buy the Full Report for...
-
Company Insights
Innovation and Patenting activity of Intercept Pharmaceuticals Inc Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Intercept Pharmaceuticals Inc Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewAlcoholic Hepatitis – Drugs In Development, 2024
Empower your strategies with our Alcoholic Hepatitis – Drugs In Development, 2024 report and make more profitable business decisions. Alcoholic hepatitis is inflammation of the liver caused by excessive alcohol consumption over a long period of time. Symptoms include changes in appetite, dry mouth, weight loss, yellowing of the skin or eyes (jaundice), fever, and fatigue. Risk factors include alcohol use, obesity, and genetic factors. Treatment includes corticosteroids and liver transplant. The Alcoholic Hepatitis drugs in development market research report provide...
-
Product Insights
NewPrimary Biliary Cholangitis (Primary Biliary Cirrhosis) – Drugs In Development, 2024
Empower your strategies with our Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Drugs In Development, 2024 report and make more profitable business decisions. Primary biliary cirrhosis is a chronic disease of the liver that slowly destroys the bile ducts within the liver. Symptoms include fatigue, itchy skin, dry eyes, jaundice, swollen feet and ankles, pain in the upper right portion of the abdomen, and diarrhea. Predisposing factors include age and history of infections. Treatment includes bile acid sequestrants and liver transplantation....
-
Product Insights
NewLiver Cirrhosis – Drugs In Development, 2024
Empower your strategies with our Liver Cirrhosis – Drugs In Development, 2024 report and make more profitable business decisions. Cirrhosis is scarring of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcohol abuse. The scar tissue damages the normal structure of the liver, which affects the normal flow of blood through the liver. Symptoms include loss of appetite, itchy skin, weight loss, tiredness and weakness, and nausea. Treatment includes liver transplant surgery. The...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INT-787 in Alcoholic Hepatitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - INT-787 in Alcoholic Hepatitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.INT-787 in Alcoholic HepatitisDrug Details:INT-787 is under development for the treatment of severe...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Bezafibrate + Obeticholic Acid) in Primary Biliary Cholangitis (Primary Biliary Cirrhosis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Bezafibrate + Obeticholic Acid) in Primary Biliary Cholangitis (Primary Biliary Cirrhosis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.(Bezafibrate + Obeticholic Acid) in Primary...
-
Thematic Analysis
Hypersonic Technologies – Thematic Intelligence
Hypersonic Technologies Theme Analysis Report Overview The increasing multi-polarity (and certainly the war in Ukraine) has driven intense investment by countries such as Russia, China, and the US in hypersonic technologies. These countries are all testing hypersonic technology, generating fears of escalating global competition for weaponry that has the potential to render current defenses inadequate. For instance, Russia’s use of hypersonic missiles in Ukraine has been confirmed, representing the first combat use of these weapons, and Ukraine has claimed the...